Small-molecule inhibitor leads of Ribosome-inactivating proteins developed using the doorstop approach

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Pang, Yuan Ping ^a   Park, Jewn Giew ^a   Wang, Shaohua ^a   Vummenthala, Anuradha ^a   Mishra, Rajesh K ^a,d   McLaughlin, John E ^b   Di, Rong ^b   Kahn, Jennifer Nielsen ^b   Tumer, Nilgun E ^b   Janosi, Laszlo ^c   Davis, Jon ^c,e   Millard, Charles B ^c,f  

^a MAYO CLINIC   (United States)

^b Rutgers University   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^f Medical Identification and Treatment Systems (MITS)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1,3 DIOXOISOINDOLIN 2 YL)ACETIC ACID; 2 [2 (4 DIMETHYLAMINO)BENZYLIDENE]HYDRAZINYL BENZOIC ACID; 3 (1,3 DIOXOISOINDOLIN 2 YL)PROPANOIC ACID; 3 (5 CHLORO 2 OXOINDOLIN 3 YLIDENEAMINO)BENZOIC ACID; 3 (5,6 DICHLORO 1,3 DIOXOISOINDOLIN 2 YL)PROPANOIC ACID; 3 [2 (4 ISOPROPYLBENZYLIDENE)HYDRAZINYL]BENZOIC ACID; 4 (1,3 DIOXOISOINDOLIN 2 YL)BUTANOIC ACID; 4 [[(4 ETHOXYCARBONYL) 5 METHYL 3 OXO 1H PYRROL 2 (3H) YLIDENE]METHYL]BENZOIC ACID; 4 [[(4 METHOXYCARBONYL) 5 METHYL 3 OXO 1H PYRROL 2 (3H) YLIDENE]METHYL]BENZOIC ACID; PROTEIN INHIBITOR; RIBOSOME INACTIVATING PROTEIN; RICIN; TYROSINE; UNCLASSIFIED DRUG; VEROTOXIN 2; POLYNUCLEOTIDE;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SCREENING; DRUG STRUCTURE; INHIBITION KINETICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PROTEIN CONFORMATION; PROTEIN FUNCTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; TUMOR CELL LINE;

ESCHERICHIA COLI; MAMMALIA; RICINUS COMMUNIS;

ANIMALS; CELL LINE, TUMOR; MICE; MOLECULAR STRUCTURE; POLYNUCLEOTIDES; RIBOSOME INACTIVATING PROTEINS; RICIN; SHIGA TOXIN 2;

EID: 79953065234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017883     Document Type: Article

References (73)

1. Johannes L, Römer W, (2010) Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol 8: 105-116.
2. Snedeker KG, Shaw DJ, Locking ME, Prescott RJ, (2009) Primary and secondary cases in Escherichia coli O157 outbreaks: a statistical analysis. BMC Infect Dis 9: 144.
3. Boyce TG, Swerdlow DL, Griffin PM, (1995) Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 333: 364-368.
4. Audi J, Belson M, Patel M, Schier J, Osterloh J, (2005) Ricin poisoning: a comprehensive review. JAMA 294: 2342-2351.
5. Olsnes S, (2004) The history of ricin, abrin and related toxins. Toxicon 44: 361-370.
6. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, et al. (1988) Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171: 45-50.
7. Szewczak AA, Moore PB, Chan Y-L, Wool IG, (1993) The conformation of the sarcin/ricin loop from 28S ribosomal RNA. Proc Natl Acad Sci USA 90: 9581-9585.
8. O'Brien AD, Holmes RK, (1987) Shiga and Shiga-like toxins. Microbiol Rev 51: 206-220.
9. Kim Y, Robertus JD, (1992) Analysis of several key active-site residues of ricin-A chain by mutagenesis and x-ray crystallography. Protein Eng 5: 775-779.
10. Kim Y, Mlsna D, Monzingo AF, Ready MP, Frankel A, et al. (1992) Structure of a ricin mutant showing rescue of activity by a noncatalytic residue. Biochemistry 31: 3294-3296.
11. Chen X-Y, Berti PJ, Schramm VL, (2000) Ricin A-chain: kinetic isotope effects and transition state structure with stem-loop RNA. J Am Chem Soc 122: 1609-1617.
12. Chen X-Y, Berti PJ, Schramm VL, (2000) Transition-state analysis for depurination of DNA by ricin A-chain. J Am Chem Soc 122: 6527-6534.
13. Ho MC, Sturm MB, Almo SC, Schramm VL, (2009) Transition state analogues in structures of ricin and saporin ribosome-inactivating proteins. Proc Natl Acad Sci USA 106: 20276-20281.
14. Ekström F, Hörnberg A, Artursson E, Hammarström L-G, Schneider G, et al. (2009) Structure of HI-6•sarin-acetylcholinesterase determined by X-ray crystallography and molecular dynamics simulation: reactivator mechanism and design. PLoS ONE 4: e5957.
15. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ, (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6: 559-565.
16. Roday S, Amukele T, Evans GB, Tyler PC, Furneaux RH, et al. (2004) Inhibition of ricin A-chain with pyrrolidine mimics of the oxacarbenium ion transition state. Biochemistry 43: 4923-4933.
17. Sturm MB, Roday S, Schramm VL, (2007) Circular DNA and DNA/RNA hybrid molecules as scaffolds for Ricin inhibitor design. J Am Chem Soc 129: 5544-5550.
18. Roday S, Saen-oon S, Schramm VL, (2007) Vinyldeoxyadenosine in a sarcin-ricin RNA loop and its binding to ricin toxin A-chain. Biochemistry 46: 6169-6182.
19. Sturm MB, Tyler PC, Evans GB, Schramm VL, (2009) Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein. Biochemistry 48: 9941-9948.
20. Saenz JB, Doggett TA, Haslam DB, (2007) Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect Immun 75: 4552-4561.
21. Stechmann B, Bai S-K, Gobbo E, Lopez R, Merer G, et al. (2010) Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell 141: 231-242.
22. Wahome PG, Bai Y, Neal LM, Robertus JD, Mantis NJ, (2010) Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen. Toxicon pp. 1-12.
23. Yan X, Hollis T, Svinth M, Day P, Monzingo AF, et al. (1997) Structure-based identification of a ricin inhibitor. J Mol Biol 266: 1043-1049.
24. Miller DJ, Ravikumar K, Shen H, Suh JK, Kerwin SM, et al. (2002) Structure-based design and characterization of novel platforms for ricin and shiga toxin inhibition. J Med Chem 45: 90-98.
25. Bai Y, Monzingo AF, Robertus JD, (2009) The X-ray structure of ricin A chain with a novel inhibitor. Arch Biochem Biophys 483: 23-28.
26. Korennykh AV, Piccirilli JA, Correll CC, (2006) The electrostatic character of the ribosomal surface enables extraordinarily rapid target location by ribotoxins. Nat Struct Mol Biol 13: 436-443.
27. Korennykh AV, Plantinga MJ, Correll CC, Piccirilli JA, (2007) Linkage between substrate recognition and catalysis during cleavage of sarcin/ricin loop RNA by restrictocin. Biochemistry 46: 12744-12756.
28. Too PH, Ma MK, Mak AN, Wong YT, Tung CK, et al. (2009) The C-terminal fragment of the ribosomal P protein complexed to trichosanthin reveals the interaction between the ribosome-inactivating protein and the ribosome. Nucleic Acids Res 37: 602-610.
29. Li XP, Chiou JC, Remacha M, Ballesta JP, Tumer NE, (2009) A two-step binding model proposed for the electrostatic interactions of ricin a chain with ribosomes. Biochemistry 48: 3853-3863.
30. Kim Y, Robertus JD, (1992) Analysis of several key active site residues of ricin A chain by mutagenesis and X-ray crystallography. Protein Eng 5: 775-779.
31. Monzingo AF, Robertus JD, (1992) X-ray analysis of substrate analogs in the ricin A-chain active site. J Mol Biol 227: 1136-1145.
32. Weston SA, Tucker AD, Thatcher DR, Derbyshire DJ, Pauptit RA, (1994) X-ray structure of recombinant ricin A-chain at 1.8 A resolution. J Mol Biol 244: 410-422.
33. Mlsna D, Monzingo AF, Katzin BJ, Ernst S, Robertus JD, (1993) Structure of recombinant ricin A-chain at 2.3 angstrom. Protein Sci 2: 429-435.
34. Rutenber E, Katzin BJ, Ernst S, Collins EJ, Mlsna D, et al. (1991) Crystallographic refinement of ricin to 2.5 A. Proteins 10: 240-250.
35. Pang Y-P, Perola E, Xu K, Prendergast FG, (2001) EUDOC: a computer program for identification of drug interaction sites in macromolecules and drug leads from chemical databases. J Comput Chem 22: 1750-1771.
36. Wang Q, Pang Y-P, (2007) Accurate reproduction of 161 small-molecule complex crystal structures using the EUDOC program: expanding the use of EUDOC to supramolecular chemistry. PLoS ONE 2: e531.
37. Pang YP, Mullins TJ, Swartz BA, McAllister JS, Smith BE, et al. (2008) EUDOC on the IBM Blue Gene/L system: Accelerating the transfer of drug discoveries from laboratory to patient. IBM J Res Dev 52: 69-82.
38. Perola E, Xu K, Kollmeyer TM, Kaufmann SH, Prendergast FG, et al. (2000) Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. J Med Chem 43: 401-408.
39. Pang Y-P, Xu K, Kollmeyer TM, Perola E, McGrath WJ, et al. (2001) Discovery of a new inhibitor lead of adenovirus proteinase: steps toward selective, irreversible inhibitors of cysteine proteinases. FEBS Lett 502: 93-97.
40. Dooley AJ, Shindo N, Taggart B, Park JG, Pang Y-P, (2006) From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus. Bioorg Med Chem Lett 16: 830-833.
41. Tan C, Wei L, Ottensmeyer PF, Goldfine I, Maddux BA, et al. (2004) Structure-based de novo design of ligands using a three-dimensional model of the insulin receptor. Bioorg Med Chem Lett 14: 1407-1410.
42. Corwin AH, Doak KW, (1955) Kinetics of the condensation of dipyrrylmethenes with an α-free pyrrole. J Am Chem Soc 77: 464-469.
43. Braibante MEF, Braibante HTS, Costa CC, Martins DB, (2002) Reactivity of choloracetylated beta-enamino compounds. Synthesis of heterocycles. Tetrahedron Lett 43: 8079-8081.
44. Davoll J, (1953) 777. The preparation and structure of some derivatives of 3-hydroxypyrrole. J Chem Soc pp. 3802-38011.
45. Galdino SL, da Rocha Pitta I, Luu-Duc eC, Lucena B, Oliveira Correa Lima eR, (1985) Benzylidene-5 pyrrolones, furannones et thiophenones I.- synthese, structre et activities pharmacologiques. Eur J Med- Chim Ther 5: 439-442.
46. Iizuka N, Sarnow P, (1997) Translation-competent extracts from Saccharomyces cerevisiae: effects of L-A RNA, 5′ cap, and 3′ poly(A) tail on translational efficiency of mRNAs. Methods 11: 353-360.
47. Nakatsu T, Ichiyama S, Hiratake J, Saldanha A, Kobashi N, et al. (2006) Structural basis for the spectral difference in luciferase bioluminescence. Nature 440: 372-376.
48. Auld DS, Thorne N, Maguire WF, Inglese J, (2009) Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA 106: 3585-3590.
49. Janosi L, Alving CR, Matyas GR, (2006) A colorimetric cell viability assay for determining ricin neutralizing antibody titers. ASM Biodefense Research Meeting pp. 218(F).
50. Fraser ME, Fujinaga M, Cherney MM, Melton-Celsa AR, Twiddy EM, et al. (2004) Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 279: 27511-27517.
51. Auld DS, Thorne N, Nguyen D-T, Inglese J, (2008) A specific mechanism for nonspecific activation in reporter-gene assays. ACS Chem Biol 3: 463-470.
52. Auld DS, Lovell S, Thorne N, Lea WA, Maloney DJ, et al. (2010) Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci USA 107: 4878-4883.
53. Kim YG, Muralinath M, Brandt T, Pearcy M, Hauns K, et al. (2003) A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci USA 100: 6974-6979.
54. Kahmann JD, Wecking DA, Putter V, Lowenhaupt K, Kim Y-G, et al. (2004) The solution structure of the N-terminal domain of E3L shows a tyrosine conformation that may explain its reduced affinity to Z-DNA in vitro. Proc Natl Acad Sci USA 101: 2712-2717.
55. Kim Y-G, Muralinath M, Brandt T, Pearcy M, Hauns K, et al. (2003) A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci USA 100: 6974-6979.
56. Fan F, Wood KV, (2007) Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 5: 127-136.
57. Heitman LH, van Veldhoven JPD, Zweemer AM, Ye K, Brussee J, et al. (2008) False positives in a reporter gene assay: identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase. J Med Chem 51: 4724-4729.
58. Kora FA, Khalaf NS, Abdel-Ghaffar SA, Fodah NS, El-Naggar AM, (1986) Synthesis and antimicrobial activity of some new 4,5-dichlorphthaloyl amino acid derivatives. J Serb Chem Soc 51: 529-535.
59. Reyes A, Juaristi E, (2000) Stereo selective alkylation of C2-symmetric chiral N-phthaloyl glycinamides in the preparation of enantiopure alfa-amino acids. Tetrahedron Asymmetr 11: 1411-1423.
60. Benary E, Silbermann B, (1913) Synthese von oxy-pyrrol-und pyrrolin-derivaten aus amino-crotonsaureester. Ber der Dtsch Chem Ges 46: 1363-1377.
61. Cieplak P, Cornell WD, Bayly C, Kollman PA, (1995) Application of the multimolecule and multiconformational RESP methodology to biopolymers: charge derivation for DNA, RNA, and proteins. J Comput Chem 16: 1357-1377.
62. Frisch MJ, Trucks GW, Schlegel HB, Gill PMW, Johnson BG, et al. (1999) GAUSSIAN 98, Revision A.7. Gaussian, Inc Pittsburgh, PA.
63. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE III, et al. (1995) AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 91: 1-41.
64. Jorgensen WL, Chandreskhar J, Madura JD, Impey RW, Klein ML, (1982) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
65. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
66. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
67. Wickstrom L, Okur A, Simmerling C, (2009) Evaluating the performance of the ff99SB force field based on NMR scalar coupling data. Biophys J 97: 853-856.
68. Berendsen HJC, Postma JPM, van Gunsteren WF, Di Nola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690.
69. Darden TA, York DM, Pedersen LG, (1993) Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
70. Melton-Celsa AR, Darnell SC, O'Brien AD, (1996) Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice. Infect Immun 64: 1569-1576.
71. Melton-Celsa AR, Kokai-Kun JF, O'Brien AD, (2002) Activation of Shiga toxin type 2d (Stx2d) by elastase involves cleavage of the C-terminal two amino acids of the A2 peptide in the context of the appropriate B pentamer. Mol Microbiol 43: 207-215.
72. Obrig TG, Moran TP, Brown JE, (1987) The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 244: 287-294.
73. Shimizu T, Sato T, Kawakami S, Ohta T, Noda M, et al. (2007) Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity. Microb Pathog 43: 88-95.